Video: DIAMOND study provides ‘interesting data’ on hyperkalemia reduction

In this video, David E. Lanfear, MD, advanced HF specialist and program director of the Advanced Heart Failure Fellowship at the Henry Ford Health System in Detroit, spoke to Healio about two clinical trials presented at the American College of Cardiology Scientific Session.
Lanfear focused on the hypertrophic cardiomyopathy (HCM) study that showed “very good benefit” in terms of quality of life.
He also discussed the DIAMOND study, which provided “interesting data for heart failure” in a patiromer that could reduce hyperkalemia in patients with HF.

In this video, David E. Lanfear, MD, advanced HF specialist and program director of the Advanced Heart Failure Fellowship at the Henry Ford Health System in Detroit, spoke to Healio about two clinical trials presented at the American College of Cardiology Scientific Session.
Lanfear focused on the hypertrophic cardiomyopathy (HCM) study that showed “very good benefit” in terms of quality of life.
He also discussed the DIAMOND study, which provided “interesting data for heart failure” in a patiromer that could reduce hyperkalemia in patients with HF.